Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues
Naunyn-Schmiedeberg's Archives of Pharmacology · 2023
DOI: 10.1007/s00210-023-02421-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2023. Verfasst von Friederike Elisabeth Ugi Meyer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany. Hauptthemen laut MEDLINE: Fibroblasts, Connective Tissue. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung., German Centre for Cardiovascular Research.
Abstract (Originalsprache)
The anti-fibrotic drug pirfenidone (PFD) is currently in clinical testing for the treatment of heart failure with preserved ejection fraction; however, its effects on human cardiac cells have not been fully investigated. Therefore, we aimed to characterize the impact of PFD on human cardiac fibroblasts (CF) in 2D culture as well as in 3D-engineered connective tissues (ECT). We analyzed proliferation by automated cell counting and changes in signaling by immunoblotting. We generated ECT with different geometries to modify the cellular phenotype and investigated the effects of PFD on cell number and viability as well as on cell cycle activity. We further studied its effect on ECT compaction, contraction, stiffening, and strain resistance by ECT imaging, pole deflection analysis, and ultimate tensile testing. Our data demonstrate that PFD inhibits human CF proliferation in a concentration-dependent manner with an IC 50 of 0.43 mg/ml and its anti-mitogenic effect was further corroborated by an inhibition of MEK1/2, ERK1/2, and riboprotein S6 (rpS6) phosphorylation. In ECT, a lower cell cycle activity was found in PFD-treated ECT and fewer cells resided in these ECT after 5 days of culture compared to the control. Moreover, ECT compaction as well as ECT contraction was impaired. Consequently, biomechanical analyses demonstrated that PFD reduced the stiffness of ECT. Taken together, our data demonstrate that the anti-fibrotic action of PFD on human CF is based on its anti-mitogenic effect in 2D cultures and ECT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
- Randall Centre for Cell and Molecular Biophysics, Kings College London, London, UK.
- DZHK (German Centre for Cardiovascular Research) Partner Site, Goettingen, Germany.
- Institute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany. Susanne.Lutz@med.uni-goettingen.de.
- DZHK (German Centre for Cardiovascular Research) Partner Site, Goettingen, Germany. Susanne.Lutz@med.uni-goettingen.de.
Förderung
- Deutsche Forschungsgemeinschaft
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- German Centre for Cardiovascular Research
- Georg-August-Universität Göttingen
Zitieren
APA
Meyer, F. E. U., Santos, G. L., Doan, T. P., DeGrave, A. N., Bues, B., & Lutz, S. (2023). Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02421-9
Vancouver
Meyer FEU, Santos GL, Doan TP, DeGrave AN, Bues B, Lutz S. Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023. doi:10.1007/s00210-023-02421-9
BibTeX
@article{Meyer2023,
author = {Meyer, Friederike Elisabeth Ugi and Santos, Gabriela Leao and Doan, Thao Phuong and DeGrave, Alisa Nicole and Bues, Bastian and Lutz, Susanne},
title = {Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2023},
doi = {10.1007/s00210-023-02421-9}
}
EUVIMED